Document:

Exhibit
10.1

 

TECHCARE
CORP.

COMMON
STOCK PURCHASE AGREEMENT

 

This
Common Stock Purchase Agreement (this “Agreement”) is dated as of January 6, 2020, and is among TechCare Corp.,
a Delaware corporation (the “Company”), the Company’s directors and Citrine S A L Investment & Holdings
Ltd. on behalf of itself and/or any of its limited partners and/or any other entities, as designated by it from time to time (“Investor”).
Details of any limited partners or other entities so designated by Investor will be appended hereto prior to the Closing.

 

SECTION
1: SALE AND ISSUANCE

 

	1.1	Sale
    and Issuance of Shares. Subject to the terms and conditions of this Agreement, Investor agrees to purchase, and the Company
    agrees to sell and issue to Investor, 893,509,276 shares of the Company’s common stock, par value $0.0001 per share
    (the “Common Stock”), which represents 95% of the fully diluted capital stock of the Company as of immediately
    following the Closing (the “Shares”), at an aggregate purchase price of $150,000 (the “Purchase
    Price”). The Purchase Price may at the Investor’s discretion be paid in the form of a loan. The number of
    shares to be issued to Investor will be adjusted as necessary such that it represents 95% of the fully diluted capital stock
    of the Company as of immediately following the Closing.
	 	 
	1.2	Use
    of Proceeds – it is hereby agreed that the full Purchase Price, together with an equity investment to be paid by
    YMY Industry Ltd. prior to the Closing (the “YMY Investment”), shall be transferred by the Company to its
    subsidiary, Novomic, within five business days following the Closing. Neither the Company and/or Citrine (and/or any others
    on each of their behalf) shall have any right, claim and/or demand towards Novomic (and/or any others on its behalf) regarding
    the transfer and utilization of such funds, as aforesaid in this Section 1.2.

 

SECTION
2: CLOSING DATES AND DELIVERY

 

2.1
Closing. The purchase, sale and issuance of the Shares (the “Closing”) shall take place as soon as practicable,
provided that all the conditions to the Closing set forth in Section 6 are satisfied or waived, or such later date as the Company
and the Investor shall mutually agree (the “Closing Date”). Each party to this Agreement shall work expeditiously
and in good faith to procure the satisfaction of all the conditions to Closing set forth in Section 6 of this Agreement. If 20
days following the signing of this Agreement the Novomic Divestment has for any reason (which may include delay in obtaining SEC
approval for the Company’s 14-C filing) not been completed, the Closing shall, at Investor’s discretion, take place
notwithstanding section 6.2(b) hereof, provided all other conditions to Closing set forth in Section 6 have been satisfied or
waived. Investor may at its discretion defer the Closing for an additional period or periods determined by it to enable the Novomic
Divestment to be completed prior to Closing. All costs associated with Novomic after the Closing will be borne by Novomic and
not by the Company whether or not the Novomic Divestment has been completed.

 

2.2
Delivery. On the Closing Date, the Company shall deliver the following:

 

	 	(a)	this
    Agreement duly executed by the Company; and
	 	 	 
	 	(b)	the
    certificates representing the Shares to the Investor, which shall be registered in such name or names as Investor may request,
    which delivery shall be made against payment of the Purchase Price for the Shares, by wire transfer within five business days
    following the Closing in accordance with the Company’s written instructions.

 

SECTION
3: REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The
Company and each of its directors hereby represent and warrant to Investor as follows, and shall each be jointly and severally
liable in respect of a breach of these representations and warranties:

 

3.1
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware and has the requisite corporate power and authority to execute and deliver this Agreement
and all other documents required to be executed and delivered by the Company in connection with this Agreement (collectively,
with the Agreement, the “Transaction Documents”), to perform its obligations hereunder and thereunder, and
to issue and deliver the Shares and has taken all necessary corporate action to authorize the execution, delivery and performance
of the Transaction Documents.

 

    	 	 	 

     

    

 

3.2
Subsidiary. As of the Closing, subject to section 2.1 hereof, the Company will own 10% of the fully diluted capital stock
of Novomic Ltd., an Israeli company (“Novomic”), and has divested, all other holdings in Novomic (the “Novomic
Divestment”). The Company will have obtained all necessary authorizations, including without limitation corporate, shareholder
and other approvals for the Novomic Divestment. Novomic is duly organized, validly existing and in good standing under the laws
of Israel. If for any reason the Closing occurs prior to completion of the Novomic Divestment, the Company will not be obliged
to bear any costs associated with Novomic.

 

3.3
Capitalization.

 

(a)
As of the date of this Agreement, the authorized capital stock of the Company consists of 500,000,000 shares of Common Stock,
of which 35,449,398 shares are issued and outstanding, and 50,000,000 shares of Preferred Stock, par value $0.0001 per share,
of which 10,334,828 are issued and outstanding. Prior to the Closing, the Company will issue 931,034 shares of Common Stock to
YMY Industry Ltd. in consideration for the YMY Investment. As of immediately preceding the Closing, the authorized capital stock
of the Company consists of 1,500,000,000 shares of Common Stock, of which 940,536,080 shares are issued and outstanding, and 50,000,000
shares of Preferred Stock, par value $0.0001 per share, none of which are issued and outstanding. The Shares shall have the rights,
preferences, privileges and restrictions set forth in the Company’s Certificate of Incorporation as currently in effect
(the “Charter”). The Company has made available to Investor the Charter as an attachment to its SEC filing
on Form 10K of March 28, 2019, and no steps have been taken by the board of directors or any stockholder of the Company to authorize
or effect any amendment or other modification to the Charter except to effect the change from 500,000,000 to 1,500,000,000 shares
of Common Stock in the authorized capital stock of the Company.

 

(b)
As of the date of this Agreement, there are outstanding options to purchase 2,308,532 shares of Common Stock, and there are outstanding
warrants to purchase 920,001 shares of Common Stock and preferred stock. As of the Closing, there are no options, warrants, convertible
securities or other rights, agreements or arrangements to purchase any of the Company’s authorized and unissued capital
stock and no shares of capital stock of the Company are reserved for issuance, except for 931,034 shares of Common Stock to be
issued prior to the Closing to YMY Industry Ltd. in consideration for the YMY investment, 311,544 options to purchase shares of
Common Stock and an aggregate of 2,000,000 shares of Common Stock of the Company reserved for issuance pursuant to the Company’s
2018 Stock Incentive Plan. The Company is not subject to any agreement, arrangement or other obligation with respect to the registration
of any securities of the Company.

 

(c)
All issued and outstanding shares of the Company’s capital stock (i) have been duly authorized and validly issued and are
fully paid and non-assessable, and (ii) were issued in compliance with all applicable state and federal laws concerning the issuance
of securities.

 

(d)
As of the Closing, the Company has reserved the Shares for issuance pursuant to this Agreement. The Shares, when issued and delivered
and paid for in compliance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable. The Shares
will be free of any preemptive or similar rights, taxes, charges, liens or encumbrances.

 

(e)
The data on shareholders’ holdings of Common Stock and preferred stock attached hereto as Appendix A are accurate
as of December 31, 2019 and have not since such date changed materially or to an extent which would impair the Company’s
ability to fulfill its obligations under the Transaction Documents.

 

3.4
Authorization.

 

All
corporate action on the part of the Company and its directors, officers and stockholders necessary for the authorization, execution
and delivery of each of the Transaction Documents by the Company, the authorization, sale, issuance and delivery of the Shares,
the Novomic Divestment, and the performance of all of the Company’s obligations under each of the Transaction Documents
has been taken or will be taken prior to the Closing. Each of the Transaction Documents constitutes valid and binding obligations
of the Company, enforceable in accordance with their terms.

 

    	 	 	 

     

    

 

3.5
No Conflict.

 

	(a)	The
    execution and delivery by the Company of this Agreement, the execution and delivery by the Company of each of the other Transaction
    Documents to which it is or will be a party do not, and the consummation by the Company of the transactions contemplated hereby
    and thereby will not, conflict with, or result in any violation of or constitute a default (with or without notice or lapse
    of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or the loss
    of a material benefit under, or the creation of any lien or encumbrance pursuant to (i) any provision of the certificate of
    incorporation or bylaws or comparable organizational documents of the Company or Novomic, or (ii) any judgment, order, decree,
    statute, law, ordinance, rule or regulation applicable to the Company or Novomic or Novomic’s properties or assets,
    except in the case of clause (ii), which would not materially impair the Company’s ability to fulfill its obligations
    under the Transaction Documents or have a material effect on the business or operations of the Company and Novomic, taken
    as a whole.
	 	 
	(b)	No
    consent, approval, order or authorization of, notice to, or registration, declaration or filing with any court, administrative
    agency or commission or other governmental authority or instrumentality, domestic or foreign, including any industry self-regulatory
    organization (a “governmental authority”) is required by or with respect to the Company or Novomic in connection
    with the execution and delivery by the Company of this Agreement or any of the Transaction Documents or the consummation by
    the Company of the transactions contemplated hereby and thereby, except for any required notices of sale of securities filed
    with the U.S. Securities and Exchange Commission (“SEC”) and state securities agencies.

 

3.6
SEC Filings.

 

	(a)	The
    Company has made available to Investor through the SEC’s website all of its periodic reports, statements, schedules
    and registration statements filed with the SEC since August 4, 2010 (the documents referred to in this Section 3.6(a), collectively,
    the “SEC Filings”).
	 	 
	(b)	Since
    August 4, 2010, the Company has filed with or furnished to the SEC each report, statement, schedule, form or other document
    or filing required by applicable law to be filed or furnished at or prior to the time so required. As of its filing date,
    each SEC Filing complied as to form in all material respects with the applicable requirements of the Securities Act of 1933,
    as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange
    Act”), as the case may be and the SEC Filings do not contain any untrue statement of a material fact or omit to
    state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which
    they were made, not misleading.

 

3.7
Financial Statements. The audited consolidated financial statements and unaudited condensed consolidated financial statements
of the Company included in the SEC Filings (i) comply as to form, as of their respective filing dates with the SEC, in all material
respects with the applicable accounting requirements and the published rules and regulations of the SEC with respect thereto,
(ii) have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applied on
a consistent basis during the periods involved (except, in the case of unaudited statements, for the absence of footnotes), and
(iii) fairly present the consolidated financial position of the Company and its consolidated subsidiaries as of the dates thereof
and their consolidated results of operations and cash flows for the periods then ended (subject to normal year-end adjustments
in the case of any unaudited interim financial statements).

 

3.8
No Material Undisclosed Liabilities. Other than ongoing liabilities towards service providers listed in Schedule 3.9 below
and those required by applicable State or Federal law and/or the OTCQB stock exchange, there are as of the Closing no material
liabilities or obligations of the Company of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable
or otherwise. As of the Closing the Company has no outstanding tax liabilities.

 

    	 	 	 

     

    

 

3.9
Contracts and Assets. As of the Closing, except for its holding of 10% of the capital stock of Novomic, the Company is not
a party to any contracts, agreements or instruments, other than as provided in Schedule 3.9 hereof and has no properties
or assets, and except for its holding of 10% of the capital stock of Novomic, the Company has no subsidiaries and has no interest
in any other company. The Company does not have a “poison pill” or similar shareholder rights plan in effect. All
contracts to which the Company has at any time been a party (“Former Contracts”) have as of the Closing been
terminated or expired and there are no outstanding debts, obligations, restrictions or liabilities of the Company or any other
party under any Former Contracts.

 

3.10
Compliance. The Company is not in violation (i) of any term of its certificate of incorporation or bylaws, each as amended,
or (ii) of any federal or state statutes, rules or regulations the violation of which would be material to the business or operations
of the Company and Novomic, taken together as a whole.

 

3.11
Litigation. There are no material actions, suits, proceedings or investigations pending against the Company or Novomic (nor
has the Company or any of its subsidiaries received written notice of any threat thereof) before any court or governmental agency.
Neither the Company nor Novomic is a party or subject to the provisions of any material order, writ, injunction, judgment or decree
of any court or government agency or instrumentality.

 

3.12
Offering. Subject to the accuracy of Investor’s representations and warranties in Section 4, none of the Company, any
of its affiliates, or any person or entity acting on its behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would require registration of the issuance of any of the
Shares under the Securities Act, whether through integration with prior offerings or otherwise.

 

3.13
Registration Rights. The Company is presently not under any obligation and has not granted any rights to register under the
Securities Act any of its presently outstanding securities or any of its securities that may hereafter be issued.

 

3.14
Brokers or Finders. The Company has not incurred, and will not incur, directly or indirectly, as a result of any action taken
by the Company, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection
with any of the Transaction Documents or any of the transactions contemplated hereby and thereby.

 

3.15
Employees and Service Providers. As of the Closing the Company has no employees or service providers and has no outstanding
obligations or liabilities to any former employees or service providers.

 

3.16
Representations Complete. None of the representations or warranties made by the Company in this Agreement contains any untrue
statement of a material fact or omits to state any material fact necessary in order to make the statements contained herein, in
the light of the circumstances under which they were made, not misleading.

 

SECTION
4: REPRESENTATIONS AND WARRANTIES OF INVESTOR

 

Investor
hereby represents and warrants to the Company as follows:

 

4.1
Organization, Good Standing and Qualification. Investor is a company duly organized and validly existing under the laws of
Israel. Investor has the requisite corporate power and authority to execute and deliver each of the Transaction Documents to which
it is a party and to perform its obligations pursuant to the Transaction Documents.

 

4.2
Authorization. All corporate action on the part of Investor and its directors, officers and stockholders necessary for the
authorization, execution and delivery of each of the Transaction Documents to which it is a party by Investor and the performance
of all of Investor’s obligations under each of the Transaction Documents has been taken or will be taken prior to the Closing.
Each of the Transaction Documents to which it is a party constitutes valid and binding obligations of Investor, enforceable in
accordance with their terms.

 

    	 	 	 

     

    

 

4.3
No Conflict.

 

	(a)	The
    execution and delivery by Investor of this Agreement, and the execution and delivery by Investor of each of the other Transaction
    Documents to which it is or will be a party do not, and the consummation by Investor of the transactions contemplated hereby
    and thereby will not, conflict with, or result in any violation of, or constitute a default (with or without notice or lapse
    of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or the loss
    of a material benefit under, or the creation of any lien or encumbrance pursuant to (i) any provision of the certificate of
    incorporation or bylaws or comparable organizational documents of Investor, or (ii) any loan or credit agreement, note, mortgage,
    indenture, lease or other agreement, obligation or instrument to which Investor or any of its subsidiaries is a party or by
    which their respective properties or assets may be bound, or (iii) any law, permit, concession, franchise, license, judgment,
    order, decree, statute, law, ordinance, rule or regulation applicable to Investor or its properties or assets; except, in
    each case, for any of the foregoing which would not have a material and adverse effect on Investor’s ability to fulfill
    its obligations under the Transaction Documents.
	 	 
	(b)	 No
    consent, approval, order or authorization of, notice to, or registration, declaration or filing with any governmental authority
    is required by or with respect to Investor in connection with the execution and delivery by Investor of this Agreement or
    any of the Transaction Documents to which it is a party or the consummation by Investor of the transactions contemplated hereby
    and thereby.

 

4.4
Private Placement. Investor is acquiring the Shares for investment for its own account, not as a nominee or agent, and not
with the view to, or for resale in connection with, any distribution thereof. Investor has such knowledge and experience in financial
and business matters so that Investor is capable of evaluating the merits and risks of its investment in the Company. Investor
is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by the SEC under the Securities
Act.

 

4.5
Legends. Investor understands and agrees that the Shares or any other securities issued in respect of the Shares upon any
stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall bear the following legend and that
the transfer agent for the Company may be instructed that the Shares are subject to the terms of such legend:

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
LAWS OF ANY STATE, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH
ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR UNLESS SUCH REGISTRATION IS NOT REQUIRED.”

 

SECTION
5: RESERVED

 

SECTION
6: CONDITIONS TO CLOSING

 

6.1
Conditions to the Obligations of Investor. Investor’s obligation to purchase the Shares at the Closing is subject to
the fulfillment on or before the Closing of each of the following conditions, unless otherwise waived in writing by Investor:

 

	(a)	Representations
    and Warranties. The representations and warranties made by the Company and its directors in Section 3 shall be true and
    correct in all material respects as of the date hereof and as of the Closing Date as though made as of the Closing Date, except
    to the extent such representations and warranties are made only as of an earlier date, in which case as of such earlier date
    (in each case, disregarding any standards of materiality contained in such representations and warranties).
	 	 
	(b)	SEC
    filings. The Company has filed with the SEC all documents required to be filed by the Company on or prior to the Closing
    and has prepared final copies satisfactory to the counsel to Investor of all documents required to be filed by the Company
    in connection with this Agreement after the Closing.
	 	 
	(c)	Due
    Diligence. The Investor has completed to its satisfaction its due diligence review of the Company.

 

    	 	 	 

     

    

 

	(d)	Closing
    Deliverables. The Company shall have delivered to counsel to Investor the following:

 

(i)
the items set forth in Section 2.2. hereof;

 

(ii)
a certificate executed by the Chief Executive Officer, President or Chief Financial Officer of the Company on behalf of the Company
certifying the satisfaction of the conditions to closing listed in Section 6.1(a) in a form satisfactory to counsel to Investor;
and

 

(iii)
a certificate of the Company executed by the Company’s Secretary, attaching and certifying to the truth and correctness
of (1) the current certificate of incorporation of the Company, (2) the current bylaws of the Corporation and (3) all board actions
taken in connection with the transactions contemplated by this Agreement, in a form satisfactory to counsel to Investor; and

 

(iv)
a true and correct copy of a definitive information statement (the “14-C”) approved by counsel to Investor
and filed with the SEC; and

 

(iv)
a true and correct copy of an executed agreement for the purchase from the Company of 90% of the fully diluted share capital of
Novomic (“Novomic Agreement”), and a true and correct copy of a resolution of the Company’s shareholders
in a form satisfactory to counsel to Investor approving the execution, delivery and performance of the Novomic Agreement; and

 

(v)
final copies satisfactory to counsel to Investor of all documents required to be filed by the Company in connection with this
Agreement after the Closing; and

 

(vi)
letters of resignation of all the members of the board of directors, effective upon the Closing. The board shall be replaced at
the Closing by a new board appointed by Investor.

 

(vii)
to the extent reasonably practicable, copies satisfactory to counsel to Investor of waivers of options executed by the holders
listed in Schedule 6.1(d)(vii) hereof of options to purchase shares of the Company in effect as of the date of this Agreement.

 

(viii)
copies satisfactory to counsel to Investor of executed Notices of Conversion for the conversion to Common Stock of all shares
of preferred stock outstanding as of the date of this Agreement, and evidence satisfactory to counsel to Investor of the conversion
of all shares of preferred stock to shares of Common Stock and of the cancellation of the issued shares of preferred stock in
the books of the Company.

 

(ix)
copies satisfactory to counsel to Investor of executed waivers in respects of warrants to purchase shares of preferred stock in
the Company, and, to the extent reasonably practicable, warrants to purchase shares of Common Stock, executed by the holders of
warrants listed in Schedule 6.1(d)(ix) hereof in the Company.

 

(xi)
evidence satisfactory to counsel to Investor of the termination, without any surviving obligations, of all agreements with service
providers to the Company, including without limitation consulting agreements with present and former directors of the Company.

 

(xii)
documentation satisfactory to counsel to Investor for transfer of authority to Investor’s designees in, or, at Investor’s
discretion, closure of, all bank accounts of the Company.

 

(xiii)
any other documents reasonably requested by counsel to Investor as evidence of the Company’s fulfilment of its obligations
under this Agreement.

 

    	 	 	 

     

    

 

6.2
Conditions to the Obligations of the Company.

 

The
Company’s obligation to sell and issue the Shares at the Closing is subject to the fulfillment on or before such Closing
of the following conditions, unless otherwise waived in writing by the Company:

 

	(a)	The
    representations and warranties made by Investor in Section 4 shall be true and correct in all material respects as of the
    date hereof and as of the Closing Date as though made as of the Closing Date, except to the extent such representations and
    warranties are made only as of an earlier date, in which case as of such earlier date (in each case, disregarding any standards
    of materiality contained in such representations and warranties).
	 	 
	(b)	Subject
    to section 2.1 hereof, at the Closing, the Company will be clear of all operations and subsidiaries except for a 10% holding
    in Novomic.

 

SECTION
7: MISCELLANEOUS

 

7.1
Amendment; Waiver. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived,
discharged or terminated other than by a written instrument referencing this Agreement and signed by each of the Company and Investor.

 

7.2
Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered
or certified mail, postage prepaid, sent by facsimile or otherwise delivered by hand, messenger or courier service addressed:

 

	(a)	if, to Investor, to: Citrine S A L Investment &
Holdings Ltd, 3 Ha’Melacha St., Tel Aviv, Israel

 

with
a copy (which shall not constitute notice) to:

Pearl
Cohen Zedek Latzer Baratz

Azrieli
Sarona Tower

121
Menachem Begin Rd.

Tel-Aviv,
6701203, Israel

Attn:
Ilan Gerzi, Adv.

 

	(b)	if, to the Directors, to: Novomic Ltd., 23 Ha’melacha
Street Rosh Haayin, 4809173 Israel

 

with
a copy (which shall not constitute notice) to:

Zysman,
Aharoni, Gayer and Sullivan & Worcester LLP

1633
Broadway

New
York, NY 10019

Attn:
Oded Har-Even, Esq.

 

	(c)	if, to the Company, to its registered address from time
to time

 

with
copies (which shall not constitute notice) to:

Zysman,
Aharoni, Gayer and Sullivan & Worcester LLP

1633
Broadway

New
York, NY 10019

Attn:
Oded Har-Even, Esq.

 

and

 

Pearl
Cohen Zedek Latzer Baratz

Azrieli
Sarona Tower

121
Menachem Begin Rd.

Tel-Aviv,
6701203, Israel

Attn:
Ilan Gerzi, Adv.

 

    	 	 	 

     

    

 

Each
such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given when
delivered, or if sent via an internationally-recognized overnight courier service, freight prepaid, specifying next-business-day
delivery, one business day after deposit with the courier, or (ii) if sent via mail, at the earlier of its receipt or five days
after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and
mailed as aforesaid or (iii) if sent via facsimile, upon confirmation of facsimile transfer.

 

7.3
Governing Law. This Agreement shall be governed by the laws of Israel and any dispute arising from or in connection with this
Agreement shall be subject to the exclusive jurisdiction of the courts of Israel. No other forum shall have jurisdiction.

 

7.4
Expenses. Except as expressly provided herein, the Company and Investor shall each pay their own expenses in connection with
the transactions contemplated by this Agreement and the other Transaction Documents.

 

7.5
Survival. The representations, warranties, covenants and agreements made in this Agreement shall survive any investigation
made by any party hereto and the closing of the transactions contemplated hereby.

 

7.6
Successors and Assigns. This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred,
delegated or sublicensed by either party hereto without the prior written consent of the other party. Any attempt by any such
party to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Agreement in violation
of this Section 7.6 shall be null and void ab initio. Subject to the foregoing and except as otherwise provided herein, the provisions
of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators
of the parties hereto.

 

7.7
Entire Agreement. This Agreement and the other Transaction Documents, including the exhibits attached hereto and thereto,
constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof.
No party shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties,
representations or covenants except as specifically set forth herein or therein.

 

7.8
Delays or Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing
to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right,
power or remedy of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default
be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval
of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of
any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically
set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement,
shall be cumulative and not alternative.

 

7.9
Severability. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed
from this Agreement, and such court will replace such illegal, void or unenforceable provision of this Agreement with a valid
and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal,
void or unenforceable provision. The balance of this Agreement shall be enforceable in accordance with its terms.

 

7.10
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the
parties actually executing such counterparts, and all of which together shall constitute one instrument.

 

7.11
Public Announcements. The text of any public announcement made in connection with this Agreement, including any report
to the SEC made in connection with the signing hereof, shall be approved in advance by Investor.

 

(signature
page follows)

 

    	 	 	 

     

    

 

The
parties are signing this Common Stock Purchase Agreement as of the date stated in the introductory clause.

 

		 
	TechCare
    Corp.	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
		 
	Oren
    Traistman, director of TechCare Corp.	 
	 	 
		 
	Yossef
    De-Levy, director of TechCare Corp.	 
	 	 
		 
	Citrine S A L Investment & Holdings Ltd.

                                                                     
	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

    	 	 	 

     

    

 

Appendix
A

 

A
list of all holders of Common Stock and a list of all holders of Preferred A shares accurate as of December 31, 2019.

 

[Attached]

 

Schedule
6.1(d)(vii)

 

	Oren
    Traitsman	521,065	Stock
    Award Letter - April 6, 2017	Exercise
    Price - $0.0001; Expiration Date - 13/3/2022
	Shlomi
    Arbel	698,251	Stock
    Award Letters - Apr 6, 2017; Sep 3, 2017	Exercise
    Price - $0.0001; Expiration Date - 13/3/2022
	YMY
    Industry Ltd.	494,204	Stock
    Award Letter - April 6, 2017	Exercise
    Price - $0.0001; Expiration Date - 13/3/2022
	Yossef
    De-Levy	283,468	Stock
    Award Letter - April 6, 2017	Exercise
    Price - $0.0001; Expiration Date - 13/3/2022

 

Schedule
6.1(d)(ix)

 

	YMY
    Industry Ltd.	166,667	Subscription
    Agreement - April 28, 2019	Exercise
    Price - $0.6; Valid until April 28, 2020
	Oren
    Traitsman	166,667	Subscription
    Agreement - April 28, 2019	Exercise
    Price - $0.6; Valid until April 28, 2020
	Yossef
    De-Levy	41,667	Subscription
    Agreement - April 28, 2019	Exercise
    Price - $0.6; Valid until April 28, 2020
	YMY
    Industry Ltd.	200,000	Subscription
    Agreement - August 20, 2019	Exercise
    Price - $0.6; Valid until August 20, 2020
	Oren
    Traitsman	200,000	Subscription
    Agreement - August 20, 2019	Exercise
    Price - $0.6; Valid until August 20, 2020
	Oren
    Traitsman	50,000	Subscription
    Agreement - November 14, 2019	Exercise
    Price - $0.6; Valid until November 14, 2020
	YMY
    Industry Ltd.	95,000	Subscription
    Agreement - November 14, 2019	Exercise
    Price - $0.6; Valid until November 14, 2020Exhibit
10.2

 

Execution
Copy

 

SHARE
PURCHASE AGREEMENT

 

This
Share Purchase Agreement (the “Agreement”) is made and entered into as of January 6, 2020 (“Signing
Date”), by and between Traistman Radziejewski Fundacja Ltd., an Israeli Corporation (Company No. 514498856), of
10 Shaham St., Shoham, Israel (the “Buyer”); TechCare Corp. a Delaware corporation, of 1140 Avenue of
the Americas, New York 10036, NY, USA (the “Seller”); and Novomic Ltd., an Israeli corporation (Registration
No. 514243351) of 23 Ha’Melacha St. Rosh Ha’Ayin Israel (“Novomic”). (each, a “Party”, and
collectively, the “Parties”)

 

W
I T N E S S E T H:

 

WHEREAS,
the Seller has all of the rights, title and interest to the Purchased Shares (as defined below);

 

WHEREAS,
Novomic is currently at a certain risk of entering into liquidation and/or similar proceedings;

 

WHEREAS,
Buyer desires to purchase from the Seller, and the Seller desires to sell and transfer to Buyer, the Purchased Shares, upon the
terms and subject to the conditions set forth in this Agreement; and

 

NOW,
THEREFORE, for and in consideration of the premises, the mutual representations, warranties, covenants, and agreements contained
in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, hereby agree as follows:

 

ARTICLE
I

PURCHASE
AND SALE OF THE PURCHASED SHARES

 

1.1
Purchase and Sale of Shares. At the Closing (as defined below), the Seller agrees to sell and deliver to Buyer, and Buyer
agrees to purchase and acquire from the Seller, free and clear of any and all liens, pledges, security interests, encumbrances,
liabilities, 21,803 ordinary shares, constituting, immediately following the Closing, 90% (ninety percent) of the issued share
capital of Novomic.

 

1.2
In the event that the issued share capital of Novomic is higher than disclosed and represented in this Agreement under Section
1.1. above, (the “Additional Shares”), it is hereby clarified that the Buyer acquires under this Agreement also
90% of the said Additional Shares with no additional consideration and/or costs, and in the same conditions as specified herein.

 

ARTICLE
II 

LIABILITIES

 

2.1
Current and Future Liabilities. As of November 1, 2019 (the “Effective Date”), Novomic shall assume
and bear any and all of the costs and expenses relating to the operations and activities of Novomic, as such will be incurred
from time to time. Buyer shall make its best efforts to cause the release of the Seller from any liability, cost, expense, undertaking
and/or obligation in connection with Novomic, prior to the Closing. For avoidance of any doubt, the Seller hereby declares and
represents before the Buyer that as of the Effective Date, Novomic has no debts, liabilities, unpaid obligations and/or undertakings
of any kind (“Liabilities”) to the Seller and the Seller hereby waives all and any such Liabilities.

 

2.2
Past Liabilities. According to the unaudited consolidated financial reports of September 30, 2019, the outstanding debts
and liabilities of Novomic amounted to an aggregate sum of is $254,302 (two hundred and fifty four thousand, three hundred and
two US Dollars), as detailed in Schedule 2.2 attached hereto (“Past Liabilities”).

 

2.3
The Past Liabilities are to be borne and paid for by the Seller, which intends to raise such funds within the framework of: a
subscription agreement vis-à-vis YMY Industry Ltd. (attached hereto as Schedule 2.3 and an agreement for
the sale of 100% (one hundred percent) of the issued share capital of the Seller to Citrine S A L Investment & Holdings Ltd.,
or to a third party (each, an “SPA”), whereas there is no certainty that such SPA shall indeed be signed and
under which terms.

 

    	 	 	 

    	 

    

 

ARTICLE
III 

CONSIDERATION

 

3.1
Consideration. As sole consideration for the sale and delivery by the Seller to Buyer of the Purchased Shares, Buyer agrees
that Novomic, and Novomic alone, shall assume Novomic’s liabilities following the Effective Date (the “Consideration”),
pursuant to and in accordance with Section 2.1 above. For avoidance of any doubt, the Buyer itself, or any person of its behalf,
and any other executives and/or employees at Novomic, shall not assume any liabilities, past, current of future with respect to
either Novomic or the Seller, any of their subsidiary, parent companies, and any other entity, whether under this Agreement, or
not.

 

3.2
No Additional Compensation or consideration. The Parties agree that Seller shall not be entitled to any additional compensation
and/or consideration, payments, rewards and similar benefits under any competent jurisdiction and applicable law.

 

ARTICLE
IV 

REPRESENTATIONS
AND WARRANTIES OF SELLER

 

The
Seller hereby declares, warrants and represents before the Buyer as of the date hereof and as of the Closing, as follows:

 

4.1
Organization; Authorization. Seller is a corporation duly organized and validly existing under the laws of its jurisdiction
with full power and authority to own its properties and to conduct its business as currently conducted.

 

4.2
Corporate Authority. Except for the corporate actions and the approvals, authorizations, of such third parties set forth
in Schedule ‎4.2 attached hereto (the “Required Consents”), Seller has the full right, power,
legal capacity, and authority to enter into and perform its obligations hereunder and to consummate the transactions contemplated
hereby in accordance with the terms of this Agreement. Seller has taken all necessary corporate actions to authorize and approve
the execution, delivery, and performance of this Agreement and the transactions contemplated hereby. This Agreement (assuming
due authorization, execution and delivery by Buyer) constitutes the legal, valid, and binding obligation of Seller, enforceable
against Seller in accordance with its terms. Subject to receipt of the Required Consents, neither of the execution, delivery,
or performance of this Agreement, nor the consummation of the transactions contemplated by this Agreement will (i) violate, contravene,
or conflict with any provision of any of Seller’s Certificate of Incorporation or bylaws, each as amended to date, or any
constitution, law, statute, rule, regulation, injunction, judgment, order, decree, ruling, charge, or other restriction of any
government, government agency and/or committee, authority, court, or arbitrator to which Seller is subject, (ii) violate, contravene,
conflict with, constitute a breach or default (or with notice or lapse of time, or both, constitute a breach or default) under,
result in the termination or suspension of, or result in the acceleration of the performance required by, any of the terms, conditions,
or provisions of any note, bond, mortgage, indenture, debenture license, lease, agreement, commitment, property rights of any
kind, including proprietary information and intellectual property rights or other instrument or obligation to which Seller is
a party which would affect the Purchased Shares, may be subject, bound, or affected, or (iii) result in the creation or imposition
of any lien and/or any other third party rights (“Lien”) upon any of the Purchased Shares.

 

    	 	2	 

    	 

    

 

4.3
Title to Purchased Shares. Seller has good, complete and valid title to the Purchased Shares. All of the Purchased Shares
are owned by Seller, free and clear of all Lien. There are no Liens on the Purchased Shares.

 

4.4
Financial Statements. The Seller’s audited quarterly and annual financial statements (consolidated with those of
Novomic) are published via the Securities and Exchange Commission’s EDAGR system and were reviewed by the Buyer. The Financial
Statements have been prepared in accordance with generally accepted accounting principles consistently applied.

 

4.5
Litigation and Disputes. There is no claim, litigation, or proceeding pending whether at law or in equity, whether civil
or criminal in nature or by or before any governmental authority, (“Legal Proceeding”), or to Seller and Novomic’s
knowledge threatened, against the Seller and/or Novomic, jointly and severally, including any current dispute and/or other disagreement
that could rise to any future Legal Proceeding, including among others such that affects the title or interest of Seller in or
to any of the Purchased Shares or which would prevent or affect the consummation of the transactions contemplated by this Agreement
or the ownership or use by Seller or Buyer of the Purchased Shares.

 

4.6
Debt and Liabilities. Without derogating from the above, there are no liabilities or obligations of the Seller to any person
or entity that is not a party to this Agreement, whether under a third party beneficiary theory, successor liability theory, or
otherwise, with respect to the Purchased Shares, and/or in connection with this Agreement and the transactions contemplated hereby.

 

4.7
No Liquidation, Insolvency, Winding Up; Creditors. No order, writ, injunction, judgment, decree, ruling, assessment or
arbitration award of any governmental entity whatsoever (the “Order”) has been made or petition presented,
or resolution passed for the winding-up or liquidation of Seller and, there is no outstanding, nor are there circumstances that
would entitle any person and/or entity to present: (a) any petition or Order for the winding-up or administration or temporary
protection of Seller or any other property rights, including IP Rights, against Novomic, (b) any petition or order for the appointment
of a receiver over the whole or part of the undertaking of Shares of Seller and/or shares of Novomic, (c) any voluntary arrangement
between Seller and/or Novomic and any of each of their creditors, (d) any distress or execution or other process levied in respect
of Seller and/or Novomic which remains undischarged, or (e) any unfulfilled or unsatisfied judgment or court Order against Seller
and/or Novomic. Seller is not deemed unable to pay its debts within the meaning of applicable Legal Requirements and is not aware
of any circumstance that will prevent it from paying its debts as they come due in the future. Seller and Novomic operations have
not been terminated and the Seller has no plans to do so prior to Closing, including in respect to Novomic. There are no current
or past creditors of Seller and/or Novomic to whom any Legal Requirement requires the delivery of notice or from whom any form
of consent is required in conjunction with undertaking the transactions contemplated hereby in their capacity as such.

 

4.8
Brokers’ and Finders’ Fees. Neither Seller, Novomic nor each of their Representatives, has incurred, or will
incur, directly or indirectly, any liability for brokerage or finders’ fees or agents’ commissions or any similar
charges in connection with this Agreement and the transactions contemplated hereby.

 

4.9
Labor and Employment Matters.

 

Schedule
4.9 contains a list of all employees and independent contractors of Novomic, who shall continue to be engaged by Novomic
following the Effective Date, alongside with their position, date of hire, annual rate of compensation (or with respect to employees
compensated on an hourly or per diem basis, the hourly or per diem rate of compensation), estimated or target annual incentive
compensation of each such person, annual vacation, the sick and other paid time-off allowance, and other basic terms of employment,
including contributions to funds, car allowance, telephone allowance, share-based compensation and employment status of each such
person (“Benefits”), payable or which Seller is bound to provide (whether now or in the future) to each such
employee and/or independent contractor.

 

    	 	3	 

    	 

    

 

4.10
IP Rights

 

The
Seller declares, warrants and represent before the Buyer that Novomic is the sole owner of all patents and patents pending filings,
as long as exist; trademarks (including the following trademarks: “Shine by Techcare”; “Medi Shine”; “Techcare”;
“Shine”; “NOVOKID” trademark) including trademarks pending filings, codes, formulas, statistic models, clients-lists,
reputation, software, algorithms, trade-symbols, designs, copyrights and all other intellectual property rights, whether registered
or not under any applicable law (“IP Rights”) regarding all of Novomic’s business activities and operations and
no other third-parties holds any such rights, nor did the Seller or Novomic entered into any contract, agreement, commitment and/or
similar undertakings for any licensing rights of Novomic’s IP Rights to the Seller and/or any other third party. The Seller further
represent and warrants that the IP Rights are free and clear of any and all liens, pledges, interests, encumbrances and liabilities.

 

4.11
Fair Disclosure

 

Seller
and Novomic have provided to the Buyer all information required in connection with the Agreement. There is no material fact or
information relating to Novomic, its assets or that has not been set forth in disclosure provisions under this Agreement and/or
in connection herewith prior to the Closing. None of the representations or warranties made by the Seller and/or Novomic in this
Agreement or any other document, nor any of the Schedules or Exhibits attached hereto or thereto, or any other certificate furnished
by the Seller and Novomic pursuant to this Agreement, contain any untrue statement of a material fact or omits to state a material
fact necessary to fully and fairly provide the information required to be provided in any document, Schedules or Exhibits attached
hereto or thereto or any other certificate furnished by Seller and Novomic pursuant to this Agreement, or to make any statement
contained herein or therein, in light of the circumstances in which such statement was made, not misleading.

 

ARTICLE
V 

REPRESENTATIONS
AND WARRANTIES OF BUYER

 

Buyer
hereby represents and warrants to Seller as follows:

 

5.1
Organization; Authorization. Buyer is a limited company duly organized and validly existing under the laws of the State
of Israel with full power and authority to own its properties and Shares and to conduct its business as currently conducted.

 

5.2
Corporate Authority. Except for the corporate actions and the approvals, authorizations, of such third parties set forth
in Schedule ‎4.2 attached hereto (the “Required Consents”), Buyer has the full right, power,
legal capacity, and authority to enter into and perform its obligations hereunder and to consummate the transactions contemplated
hereby in accordance with the terms of this Agreement. Buyer has taken all necessary corporate actions to authorize and approve
the execution, delivery, and performance of this Agreement and the transactions contemplated hereby. This Agreement (assuming
due authorization, execution and delivery by Buyer) constitutes the legal, valid, and binding obligation of Buyer, enforceable
against Buyer in accordance with its terms. Subject to receipt of the Required Consents, neither of the execution, delivery, or
performance of this Agreement, nor the consummation of the transactions contemplated by this Agreement will (i) violate, contravene,
or conflict with any provision of any of Buyer’s Certificate of Incorporation or bylaws, each as amended to date, or any
constitution, law, statute, rule, regulation, injunction, judgment, order, decree, ruling, charge, or other restriction of any
government, government agency, court, or arbitrator to which Buyer is subject, if at all (ii) violate, contravene, conflict with,
constitute a breach or default (or with notice or lapse of time, or both, constitute a breach or default) under, result in the
termination or suspension of, or result in the acceleration of the performance required by, any of the terms, conditions, or provisions
of any note, bond, mortgage, indenture, license, lease, agreement, commitment, or other instrument or obligation to which Buyer
is a party.

 

    	 	4	 

    	 

    

 

5.3
Brokers’ and Finders’ Fees. Neither Buyer, nor any of its Representatives, has incurred, or will incur, directly
or indirectly, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection
with this Agreement and the transactions contemplated hereby.

 

5.4
Buyer’s Office. Buyer is a material shareholder of the Seller (and previously of Novomic), whereas its representative serves
as a member of the Seller’s Board since October 2016 and as its Chairman of the Board since August 2019.

 

5.5
Investment Experience. The Buyer (i) has such knowledge and experience with respect to the financial, tax and business
aspects of the Purchased Shares, (ii) is capable of evaluating the merits and risks of the transaction under this Agreement and
making an informed decision with respect thereto, in reliance, solely upon the representations and warranties presented explicitly
by the Seller and Novomic hereunder, and (ii) can bear the economic risk of an investment in the Purchased Shares, including the
complete loss thereof. The Buyer acknowledges that the Buyer has had the opportunity to ask questions of, and receive answers
from the Seller concerning the Seller and its business and to obtain any additional information, to the extent possessed by the
Seller (or to the extent it could have been acquired by the Seller without unreasonable effort or expense) necessary to verify
the accuracy of the information received by the Buyer. In connection therewith, the Buyer acknowledges that it had the opportunity
to discuss the Seller’s business, management and financial affairs with the Seller’s management. In determining whether
to enter into this Agreement, the Buyer has upon the Buyer’s own due diligence investigations.

 

ARTICLE
VI 

MUTUAL
COVENANTS OF THE PARTIES

 

The
Parties covenant with each other as follows:

 

6.1
Confidentiality. All Confidential Information furnished by Seller or Buyer to the other Party in connection with this Agreement
or the transactions contemplated by this Agreement shall be kept confidential by the Parties, and each of the Parties shall cause
such Confidential Information to be used by their respective Representatives only in connection with this Agreement and the transactions
contemplated by this Agreement. Each Party shall use its reasonable best efforts to maintain the confidentiality of the Confidential
Information, and each Party shall cause its Representatives, by instruction, agreement or otherwise, to maintain the confidentiality
of the Confidential Information under terms of confidentiality that afford no less protection to the Confidential Information
than the terms of this Agreement. Notwithstanding the above, following the Closing, Buyer will be entitled to disclose or otherwise
use in any manner whatsoever at its sole discretion any Confidential Information which is related, directly or indirectly, to
the Purchased Shares, and any confidentiality obligations set forth in this Agreement shall not apply with respect thereto; provided
that, notwithstanding the foregoing, the terms of this Agreement shall nonetheless be deemed to be Confidential Information following
the Closing. “Confidential Information” means any and all information and technology, in whatever form, including
but not limited to any and all formulae, concepts, discoveries, data, designs, ideas, inventions, methods, models, assays, research
plans, procedures, designs for experiments and tests and results of experimentation and testing (including results of research
or development), formulations, processes (including manufacturing processes, specifications and techniques), analytical and quality
control data, trial data, case report forms, data analyses, reports, manufacturing data, data and summaries and information contained
in submissions, specifications, prototypes, designs, equipment, samples, analyses, computer programs, trade secrets, data, methods,
techniques, processes, memoranda, notes, marketing and customer information, projections, non-published patent applications (together
with its attached documents) and any other data or information (in any form), as well as improvements and know-how related thereto.

 

6.2
Disclosure. Except with respect to the Required Consents and Required Notices, the Seller, nor its respective Representatives,
will issue any press releases or make any other public disclosures concerning this transaction or the contents of this Agreement
without the prior consent of the Buyer. It is agreed that the initial press release for the announcement of the transaction shall
be agreed by both Parties.

 

    	 	5	 

    	 

    

 

6.3
Non-Solicitation. Other than as specifically sated in this Agreement, for a period of 4 years starting the Effective Date,
neither Party, nor such party’s wholly owned subsidiaries, will directly or indirectly hire, solicit, recruit, induce, request,
encourage or attempt to induce or encourage, any employee of the other Party to leave the employment of the other Party or to
terminate his or her service relationship with the other Party (except with respect to General Solicitation), except in the event
of a merger or sale of all or substantially all of a Party’s shares, or a change of control effected by a sale of a Party’s
voting securities. “General Solicitation” means (a) any advertisement, article, notice or other communication
published in any newspaper, magazine or similar media or broadcast over the television or radio, whether closed circuit, or generally
available, and (b) any seminar or meeting whose attendees were invited by any general solicitation or advertising.

 

6.4
Filings and Consents. As promptly as practicable after the execution of this Agreement, each party to this Agreement (a)
shall make all filings (if any) and give all notices (if any) required to be made and given by such party in connection with the
transactions contemplated by this Agreement, and (b) shall use all commercially reasonable efforts to obtain all consents (if
any) required to be obtained (pursuant to any applicable Legal Requirements or assigned contracts, or otherwise) by such party
in connection with or to give full effect to transactions contemplated by this Agreement; provided, however, that (i) Seller shall
be responsible for making all filings with and obtaining all such consents from governmental entities pursuant to Legal Requirements
applicable to Seller or its businesses or properties, and for obtaining all such consents (if any) required to be obtained from
parties to assigned contracts by which Seller or its respective properties are bound, (ii) Buyer shall be responsible for making
all filings with and obtaining all such consents from governmental entities pursuant to Legal Requirements applicable to Buyer,
if at all, or its business or properties; and (iii) Buyer shall be obligated only to provide Seller with such assistance and information
as is reasonably required from Buyer to make such filings or to obtain such consents; provided further, that Buyer shall
not be obligated to consent to any divestitures or operational limitations or activities in connection therewith.

 

ARTICLE
VII 

CLOSING

 

7.1
The closing of the transactions contemplated by this Agreement will take place at such place mutually agreeable to Buyer and Seller,
as of the date of this Agreement (the “Closing”), or such other time and place as Buyer and Seller may agree
in writing, and in any event, no later than 30 days of the Signing Date. The obligations of the Parties to close or effect the
transactions contemplated by this Agreement will be subject to satisfaction, unless duly waived, of the applicable conditions
set forth in this Agreement. The Parties shall have the right to conduct the Closing by the exchange of executed documents through
electronic transmission and overnight courier.

 

ARTICLE
VIII 

CONDITIONS
PRECEDENT TO THE OBLIGATIONS OF SELLER

 

The
obligations of Seller to effect the transactions contemplated in this Agreement will be subject to the fulfillment, or waiver
by Seller, at or prior to the Closing of the following conditions:

 

8.1
Representations and Warranties. The representations and warranties of Buyer set forth in Article V of this Agreement
shall be true and correct in all material respects as of the Closing.

 

8.2
Performance of Obligations. Buyer shall have performed and complied in all respects with all obligations, agreements, covenants
and conditions required to be performed by it under this Agreement at or prior to the Closing.

 

    	 	6	 

    	 

    

 

8.3
Documents. Seller shall have received, in form and substance satisfactory to it, a copy of the documents, evidencing the
Buyer’s corporate actions and/or Required Consents, if and to the extent required.

 

8.4
Board of Directors of Novomic. The Buyer has taken all actions required to cause the appointment Oren Traistman, as its
representative, to the board of directors of Novomic immediately following the Closing.

 

ARTICLE
IX 

CONDITIONS
PRECEDENT TO THE OBLIGATIONS OF BUYER

 

The
obligations of Buyer to effect the transactions contemplated in this Agreement will be subject to fulfillment, or waiver by Buyer,
at or prior to the Closing of the following conditions:

 

9.1
Representations and Warranties. The representations and warranties of the Seller and Novomic, set forth in Article IV
of this Agreement shall be true and correct in all material respects as of the Closing.

 

9.2
Performance of Obligations. The Seller shall have performed and complied in all material respects with all obligations,
agreements, covenants and conditions required to be performed by it under this Agreement at or prior to the Closing.

 

9.3
Documents. Buyer shall have received, in form and substance satisfactory to it, a copy of the documents, evidencing the
Buyer’s corporate actions and/or Required Consents, if and to the extent required, including resolution of the board of directors
and/or general assembly for the transfer of the Purchased Shares; copy of any notifications to the SEC and stock exchange according
to applicable law and regulations;

 

ARTICLE
X 

INCRESE
OF CAPITAL

 

10.1
The Parties further agree that the Buyer, at its own and sole discretion, may increase the issued share capital of Novomic, at
a value that shall not be lower than one million (1,000,000) US$ , with a resolution of Novomic’s board of directors (“BOD”).
For avoidance of any doubt, Novomic BOD’s resolution for increasing Novomic’s issued share capital shall require only a majority
of BOD’s members who represent at least 50% of Novomic’s issued share capital.

 

10.2
Within 21 days of the date Novomic’s BOD decided to increase the issued share-capital, each Party shall have the right to acquire
the additional issued share capital according to its respective proportion of share-capital holding at the Effective Date of this
Agreement, and at the same value as decided by Novomic’s BOD per each issued new share.

 

10.3
If the Seller shall decide not to acquire its proportion of such increase, or any part thereof, the Buyer shall have the right
to dilute the Seller, and acquire such proportion, or part thereof, according to its sole discretion. For avoidance of any doubt,
the right under this Section 10.3. is granted to the Buyer only.

 

10.4
Without derogating from any provision under this Article X, the Buyer may, at its own and sole discretion, to loan Novomic any
amounts, and for any purpose at an annual rate of 1%, which shall be considered as first degree debt to be returned to the Buyer
vis-à-vis all other creditors, unless agreed otherwise (“Loans”). The Buyer may, at its own and sole discretion,
to return such Loans at any time, and for any reason.

 

    	 	7	 

    	 

    

 

10.5
The provisions under this Article X – Increase of Capital, shall be incorporated to Novomic’s Articles of Association (“Takanon”)(“AOA”),
and the Parties agree to amend Novomic AOA accordingly.

 

ARTICLE
XI 

MISCELLANEOUS

 

11.1
Non-Competition. In consideration of Buyer’s terms of this Agreement, and in order to enable Buyer and Novomic to
effectively protect its IP Rights and other interests, Seller agrees and undertakes that it will not, so long as the Agreement
is in effect and for a period of forty-eight (48) months following the Effective Date, Seller, and any of its officers, executives,
shareholders, employees, and any associated third parties (“Representatives”), shall not directly or indirectly
engage, establish, open or in any manner whatsoever become involved, either as an employee, owner, partner, agent, shareholder,
director, consultant or otherwise, in any business, occupation, work or any other activity and/or operations which is reasonably
likely to involve or require the use of any of Novomic’s Field of Business, as defined below. Seller and its Representatives confirm
that engagement, establishment, opening or involvement, directly or indirectly, either as owner, partner, agent, shareholder,
director, consultant or otherwise, in any business, occupation, work or any other activity which competes with the Field of Business
of Novomic as conducted during the term of employment or contemplated, during such term, to be conducted, is likely to require
the use of all or a portion of the Novomic’s IP Right and other proprietary information.

 

In
this section Field of Business shall mean: all and any products, goods, preparations, remedies, services, appliance, instruments,
techniques and similar solutions for and/or associated with: hair and/or scalp treatment, cultivation, nurture and/or pander;
and/or hair design; and/or lice and nits treatment and prevention for adults and children at all ages for all genders.

 

11.2
Taxes. Each Party to this Agreement shall bear its own taxes with regard to this Agreement according to applicable law.
Each Party shall assist, and do its best efforts to assist the other Party to complete any tax-process and/or review by any tax
authority.

 

11.3
Entire Agreement. This Agreement, including the Schedules and Exhibits hereto, constitutes the entire agreement between
the Parties with respect to the subject matter hereof and supersedes all prior agreements and understandings between the Parties.
There are no representations, warranties, undertakings or agreements between the Parties with respect to the subject matter of
this Agreement except as set forth herein.

 

11.4
Applicable Law. This Agreement shall be governed in its interpretation and performance by the laws of the State of Israel,
without reference to law pertaining to conflict of laws, and exclusively resolved by the competent courts situated in Tel Aviv-Israel
and each of the Parties hereby submits irrevocably to such jurisdiction.

 

11.5
Assignment. No Party may assign or delegate this Agreement or any rights or duties hereunder, in whole or in part, directly
or indirectly, without the prior written consent of the other Party; provided no consent shall be required in connection with
a merger, acquisition, corporate reorganization, or sale of all or substantially all of the business or Shares of such Party.
Nothing in this Agreement or any of its ancillary agreements shall limit the Buyer from selling, conveying, transferring, assigning,
licensing or delivering to any of its subsidiaries all or any portion of the Purchased Shares.

 

11.6
Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors,
and permitted assigns.

 

    	 	8	 

    	 

    

 

11.7
Construction. This Agreement shall not be construed more strictly against any Party regardless of who is responsible for
its drafting. Unless the context of this Agreement otherwise clearly requires, references to the plural include the singular and
the singular include the plural. Wherever the context so requires, the masculine shall refer to the feminine, the feminine shall
refer to the masculine, the masculine or the feminine shall refer to the neuter, and the neuter shall refer to the masculine or
the feminine. The captions of this Agreement are for convenience and ease of reference only and in no way define, describe, extend,
or limit the scope or intent of this Agreement or the intent of any of its provisions.

 

11.8
Severability. The invalidity or unenforceability of any provision of this Agreement, whether in whole or in part, shall
not in any way affect the validity and/or enforceability of any other provision of this Agreement. Any invalid or unenforceable
provisions shall be deemed severable to the extent of any such invalidity or unenforceability.

 

11.9
Amendment. This Agreement may be amended by the Parties hereto at any time by execution of an instrument in writing signed
on behalf of each of the Parties hereto.

 

11.10
Waiver. Any Party may, by written notice to another Party, (i) agree to extend the time for the performance of any of the
obligations or other actions of the other Party under this Agreement, (ii) waive any inaccuracies in the representations or warranties
of the other Party contained in this Agreement or in any document delivered pursuant to this Agreement, (iii) waive compliance
with any of the conditions or covenants of the other Party contained in this Agreement, or (iv) waive or modify performance of
any of the obligations of the other Party under this Agreement. Except as provided in the preceding sentence, no action taken
pursuant to this Agreement, including, without limitation, any investigation by or on behalf of a Party, shall be deemed to constitute
a waiver by such Party of compliance with any of the representations, warranties, covenants, conditions, or agreements contained
in this Agreement. No failure or delay on the part of a Party in exercising any right or remedy with respect to a breach of this
Agreement by another Party shall operate as a waiver thereof or of any prior or subsequent breach of this Agreement by the breaching
Party, nor shall the exercise of any such right or remedy preclude any other or future exercise thereof or exercise of any other
right or remedy in connection with this Agreement.

 

11.11
Expenses. Except as otherwise expressly provided in this Agreement, each Party will bear its respective expenses with respect
to this Agreement and the transactions contemplated hereby, including, without limitation, counsel and accountants’ fees.

 

    	 	9	 

    	 

    

 

11.12
No Third Party Beneficiaries. This Agreement is for the sole benefit of the Parties hereto and their respective successors
and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any
legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

11.13
Notices. Any notice or other communication required or permitted under this Agreement shall be in writing in English and
shall be deemed to have been given, delivered, or made, as the case may be (notwithstanding lack of actual receipt by the addressee)
(i) on the date sent if delivered personally, (ii) one (1) business day after delivery by courier or messenger service, or (iii)
upon transmission and electronic confirmation of receipt or (if transmitted and received on a non-business day) on the first business
day following transmission and electronic confirmation of receipt if sent via facsimile or email; in each case to the Parties
at the following addresses (or at such other address for a Party as shall be specified by like notice) and to the attention of
the officers identified below:

 

	If
    to Seller: 	TechCare Corp.

                                                                                          1140
                                         Avenue of the Americas, New York, NY 10036, USA

        Attention:
        Tali Dinar, CFO

        Email:
        tali@techcareltd.com

        Fax:
        + 972 3 7503057

	 	 
	If
    to Buyer:	Traistman
                                         Radziejewski Fundacja Ltd.

                                                                              10
                                         Shaham St., Shoham, Israel Attention: Oren Traistman, CEO

        Email:
        orent70@gmail.com

        Fax:
        + 972 -3-5372530

 

11.14
Electronic Signatures. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be signed (which may be executed in any number of counterparts,
each of which shall be deemed to be an original instrument, but all such counterparts together shall constitute one and the same
instrument) by their duly authorized representatives as of the day and year first above written.

 

	BUYER	 	SELLER
	 	 	 
	 	 	 
	Traistman
    Radziejewski Fundacja Ltd.	 	TechCare
    Corp.
	 	 	 
	By:	                 	 	By:	 
	Name:	 	 	Name:	          
	Title:	 	 	Title:	 

 

    	 	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]